HOOKIPA Pharma Inc has a consensus price target of $5.03, established from looking at the 25 latest analyst ratings. The last 3 analyst ratings were released from RBC Capital, HC Wainwright & Co., and RBC Capital on March 25, 2024, March 25, 2024, and January 30, 2024. With an average price target of $5.5 between RBC Capital, HC Wainwright & Co., and RBC Capital, there's an implied 643.24% upside for HOOKIPA Pharma Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/25/2024 | HOOK | Buy Now | HOOKIPA Pharma | $0.74 | 575.68% | RBC Capital | Brian Abrahams | → $5 | Reiterates | Outperform → Outperform | Get Alert |
03/25/2024 | HOOK | Buy Now | HOOKIPA Pharma | $0.74 | 778.38% | HC Wainwright & Co. | Arthur He | → $6.5 | Reiterates | Buy → Buy | Get Alert |
01/30/2024 | HOOK | Buy Now | HOOKIPA Pharma | $0.74 | 575.68% | RBC Capital | Brian Abrahams | $6 → $5 | Maintains | Outperform | Get Alert |
09/27/2023 | HOOK | Buy Now | HOOKIPA Pharma | $0.74 | 845.95% | RBC Capital | Brian Abrahams | → $7 | Reiterates | Outperform → Outperform | Get Alert |
09/06/2023 | HOOK | Buy Now | HOOKIPA Pharma | $0.74 | 440.54% | Truist Securities | Asthika Goonewardene | → $4 | Reiterates | Buy → Buy | Get Alert |
08/11/2023 | HOOK | Buy Now | HOOKIPA Pharma | $0.74 | 778.38% | HC Wainwright & Co. | Arthur He | $8 → $6.5 | Maintains | Buy | Get Alert |
06/30/2023 | HOOK | Buy Now | HOOKIPA Pharma | $0.74 | 845.95% | RBC Capital | Brian Abrahams | → $7 | Reiterates | Outperform → Outperform | Get Alert |
06/05/2023 | HOOK | Buy Now | HOOKIPA Pharma | $0.74 | 204.05% | Morgan Stanley | Vikram Purohit | $2 → $2.25 | Maintains | Equal-Weight | Get Alert |
05/12/2023 | HOOK | Buy Now | HOOKIPA Pharma | $0.74 | 981.08% | HC Wainwright & Co. | Arthur He | → $8 | Reiterates | Buy → Buy | Get Alert |
03/20/2023 | HOOK | Buy Now | HOOKIPA Pharma | $0.74 | 440.54% | Truist Securities | Asthika Goonewardene | $11 → $4 | Maintains | Buy | Get Alert |
03/16/2023 | HOOK | Buy Now | HOOKIPA Pharma | $0.74 | 981.08% | HC Wainwright & Co. | Arthur He | → $8 | Reiterates | → Buy | Get Alert |
12/02/2022 | HOOK | Buy Now | HOOKIPA Pharma | $0.74 | -32.43% | B of A Securities | Alec Stranahan | $6 → $0.5 | Downgrade | Buy → Underperform | Get Alert |
11/15/2022 | HOOK | Buy Now | HOOKIPA Pharma | $0.74 | 845.95% | RBC Capital | Brian Abrahams | $8 → $7 | Maintains | Outperform | Get Alert |
08/23/2022 | HOOK | Buy Now | HOOKIPA Pharma | $0.74 | 1386.49% | Truist Securities | Asthika Goonewardene | $16 → $11 | Maintains | Buy | Get Alert |
08/11/2022 | HOOK | Buy Now | HOOKIPA Pharma | $0.74 | 305.41% | SVB Leerink | Andrew Berens | $4 → $3 | Maintains | Outperform | Get Alert |
03/25/2022 | HOOK | Buy Now | HOOKIPA Pharma | $0.74 | 1116.22% | RBC Capital | Brian Abrahams | $11 → $9 | Maintains | Outperform | Get Alert |
02/17/2022 | HOOK | Buy Now | HOOKIPA Pharma | $0.74 | 981.08% | HC Wainwright & Co. | Swayampakula Ramakanth | $15 → $8 | Maintains | Buy | Get Alert |
02/16/2022 | HOOK | Buy Now | HOOKIPA Pharma | $0.74 | 440.54% | SVB Leerink | Andrew Berens | $3 → $4 | Maintains | Outperform | Get Alert |
11/12/2021 | HOOK | Buy Now | HOOKIPA Pharma | $0.74 | 710.81% | Morgan Stanley | Vikram Purohit | — | Downgrade | Overweight → Equal-Weight | Get Alert |
The latest price target for HOOKIPA Pharma (NASDAQ: HOOK) was reported by RBC Capital on March 25, 2024. The analyst firm set a price target for $5.00 expecting HOOK to rise to within 12 months (a possible 575.68% upside). 9 analyst firms have reported ratings in the last year.
The latest analyst rating for HOOKIPA Pharma (NASDAQ: HOOK) was provided by RBC Capital, and HOOKIPA Pharma reiterated their outperform rating.
There is no last upgrade for HOOKIPA Pharma.
The last downgrade for HOOKIPA Pharma Inc happened on December 2, 2022 when B of A Securities changed their price target from $6 to $0.5 for HOOKIPA Pharma Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of HOOKIPA Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for HOOKIPA Pharma was filed on March 25, 2024 so you should expect the next rating to be made available sometime around March 25, 2025.
While ratings are subjective and will change, the latest HOOKIPA Pharma (HOOK) rating was a reiterated with a price target of $0.00 to $5.00. The current price HOOKIPA Pharma (HOOK) is trading at is $0.74, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.